Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

Luis Paz‐Ares , Alexander Luft , David Vicente , Luis Paz‐Ares , Alexander Luft , David Vicente , Ali Tafreshi , Mahmut Gümüş , Julien Mazières , Bárbara Hermes , Filiz Çay Şenler , Tibor Csőszi , Andrea Fülöp , Jerónimo Rafael Rodríguez‐Cid , Jonathan Wilson , Shunichi Sugawara , Terufumi Kato , Ki Hyeong Lee , Ying Cheng , Silvia Novello , Balázs Halmos , Xiaodong Li , Gregory M. Lubiniecki , Bilal Piperdi , Dariusz M. Kowalski , Keynote Investigators
2018 New England Journal of Medicine 3,472 citations

Abstract

In patients with previously untreated metastatic, squamous NSCLC, the addition of pembrolizumab to chemotherapy with carboplatin plus paclitaxel or nab-paclitaxel resulted in significantly longer overall survival and progression-free survival than chemotherapy alone. (Funded by Merck Sharp & Dohme; KEYNOTE-407 ClinicalTrials.gov number, NCT02775435 .).

Keywords

PembrolizumabChemotherapyMedicineOncologyLung cancerInternal medicineCancerPD-L1Immunotherapy

Affiliated Institutions

Related Publications

Publication Info

Year
2018
Type
article
Volume
379
Issue
21
Pages
2040-2051
Citations
3472
Access
Closed

External Links

View on DOI.org

Social Impact

Altmetric
PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

3472
OpenAlex

Cite This

Luis Paz‐Ares, Alexander Luft, David Vicente et al. (2018). Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer. New England Journal of Medicine , 379 (21) , 2040-2051. https://doi.org/10.1056/nejmoa1810865

Identifiers

DOI
10.1056/nejmoa1810865